Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$781M |
| 2 |
Nike
NKE
|
+$773M |
| 3 |
ATVI
Activision Blizzard
ATVI
|
+$536M |
| 4 |
Texas Instruments
TXN
|
+$493M |
| 5 |
AGN
Allergan plc
AGN
|
+$379M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Starbucks
SBUX
|
+$1.07B |
| 2 |
Qualcomm
QCOM
|
+$673M |
| 3 |
TJX Companies
TJX
|
+$603M |
| 4 |
NVIDIA
NVDA
|
+$431M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$429M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.31% |
| 2 | Consumer Discretionary | 17.37% |
| 3 | Healthcare | 13.5% |
| 4 | Communication Services | 13.08% |
| 5 | Financials | 10.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
501
PUT
Regeneron Pharmaceuticals
REGN
$69.9B
| $6.86M | 0.01% |
17,700
| – | – |
|
502
Pembina Pipeline
PBA
$29B
| $6.69M | 0.01% |
211,048
-1,215,903
| -85% | -$38.7M |
|
|
BPMC
503
DELISTED
Blueprint Medicines
BPMC
| $6M | 0.01% |
+150,000
| New | +$5.37M |
|
|
BECN
504
DELISTED
Beacon Roofing Supply, Inc.
BECN
| $5.91M | 0.01% |
120,278
-100,023
| -45% | -$4.62M |
|
505
e.l.f. Beauty
ELF
$4.95B
| $5.76M | 0.01% |
+200,000
| New | +$5.41M |
|
|
TVRD
506
Tvardi Therapeutics
TVRD
$23.8M
| $5.52M | 0.01% |
+8,333
| New | +$4.45M |
|
|
TRHC
507
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $5.46M | 0.01% |
405,194
| – | – |
|
|
STKL
508
DELISTED
SunOpta
STKL
| $5.38M | 0.01% |
774,779
-1,815,104
| -70% | -$13M |
|
509
Surgery Partners
SGRY
$1.98B
| $5.2M | 0.01% |
266,647
-750,563
| -74% | -$14.6M |
|
|
PETX
510
DELISTED
Aratana Therapeutics, Inc.
PETX
| $5.17M | 0.01% |
975,369
-171,558
| -15% | -$1.16M |
|
|
BOLD
511
DELISTED
Audentes Therapeutics, Inc
BOLD
| $5.11M | 0.01% |
299,656
| – | – |
|
|
REVG
512
DELISTED
REV Group
REVG
| $4.78M | 0.01% |
+173,351
| New | +$4.7M |
|
513
PUT
Insmed
INSM
$22.7B
| $4.73M | 0.01% |
+270,000
| New | +$4.16M |
|
|
RARX
514
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $4.31M | ﹤0.01% |
202,500
| – | – |
|
515
Norfolk Southern
NSC
$77.1B
| $4.31M | ﹤0.01% |
38,476
-47,976
| -55% | -$5.61M |
|
|
CACB
516
DELISTED
Cascade Bancorp
CACB
| $4.29M | ﹤0.01% |
556,240
-95,148
| -15% | -$756K |
|
517
Tempest Therapeutics
TPST
$14.9M
| $4.08M | ﹤0.01% |
747
| – | – |
|
518
ExxonMobil
XOM
$642B
| $3.69M | ﹤0.01% |
45,016
-69,213
| -61% | -$5.78M |
|
519
iRhythm Holdings
IRTC
$3.69B
| $3.63M | ﹤0.01% |
96,571
-108,723
| -53% | -$3.74M |
|
520
MacroGenics
MGNX
$254M
| $3.51M | ﹤0.01% |
188,908
| – | – |
|
521
Berkshire Hathaway Class B
BRK.B
$1.07T
| $3.38M | ﹤0.01% |
20,305
-31,791
| -61% | -$5.32M |
|
522
Johnson & Johnson
JNJ
$641B
| $3.33M | ﹤0.01% |
26,745
-46,887
| -64% | -$5.6M |
|
523
State Street SPDR S&P Metals & Mining ETF
XME
$3.96B
| $3.29M | ﹤0.01% |
108,322
+1,831
| +2% | +$59K |
|
|
XL
524
DELISTED
XL Group Ltd.
XL
| $3.19M | ﹤0.01% |
79,906
-13,467
| -14% | -$528K |
|
525
Emerson Electric
EMR
$83.6B
| $3M | ﹤0.01% |
50,207
+39,797
| +382% | +$2.38M |
|
Similar funds
Jennison Associates's Q1 2017 Portfolio in Review
As of Q1 2017, Jennison Associates held 861 positions worth $93.2B, up 4.1% from $89.6B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Jennison Associates withdrew a net $4.47B in Q1 2017, closing 224 positions and reducing 376 holdings. Its most notable exit was Mobileye N.V., an estimated $165M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Jennison Associates opened a new position in Snap worth $119M.
- Jennison Associates's largest Q1 2017 buy was Snap: 5,289,727 shares worth $119M.
- Jennison Associates added most to Broadcom in Q1 2017, an estimated $781M increase.
- Jennison Associates's biggest Q1 2017 reduction was Starbucks, cutting an estimated $1.07B.
- Jennison Associates fully exited Mobileye N.V. in Q1 2017, selling an estimated $165M.
- Jennison Associates's ten largest holdings make up 26% of its $93.2B portfolio in Q1 2017.
- Jennison Associates opened 55 new positions and closed 224 in Q1 2017.
- Jennison Associates's portfolio value rose 4.1% quarter-over-quarter to $93.2B.
Based on Jennison Associates's 13F filing for Q1 2017, filed 28 Apr 2017.